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Abstract
Background: Combination chemotherapy with Western anti-tuberculosis (TB) drugs is the mainstay of TB
treatment. Chinese herbal medicines with either heat clearing and detoxifying effects or nourishing Yin and
reducing fire effects have been used to treat TB based on the Traditional Chinese Medicine (TCM) syndromes of TB
patients. This study analyzed the expression profiles of long non-coding RNAs (lncRNAs) and mRNAs in TB patients
with different TCM syndromes.
Methods: TB patients were classified as pulmonary Yin deficiency (PYD) syndrome, hyperactivity of fire due to Yin
deficiency (HFYD) syndrome, and deficiency of Qi and Yin (DQY) syndrome. Total RNA from 44 TB patients and
healthy controls was extracted and hybridized with a human lncRNA microarray containing 30586 lncRNAs and
26109 mRNAs probes. Bioinformatics analyses, including gene ontology (GO) and pathways, were performed.
Related clinical data were also analyzed.
Results: Differentially expressed mRNAs and lncRNAs were identified (fold change >2, and P < 0.05) in PYD (634
mRNAs and 566 lncRNAs), HFYD (47 mRNAs and 55 lncRNAs), and DQY (63 mRNAs and 60 lncRNAs) patients. The
most enriched pathways were the hippo signaling pathway (P = 0.000164) and the protein digestion and
absorption pathway (P = 5.89017E-05). Clinical analyses revealed that the lipid indexes of TB patients were abnormal
and that the triglyceride concentration was significantly higher in DQY patients (P = 0.0252). Our study is the first to
acquire the microarray expression profiles of lncRNAs and mRNAs and analyze pathway enrichment in PYD, HFYD,
and DQY patients with TB.
Conclusions: Our analyses of the expression profiles of lncRNAs and mRNAs may represent a novel method to
explore the biological essence of TCM syndromes of TB.
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Background
Pulmonary tuberculosis (TB) caused by Mycobacterium
tuberculosis (Mtb) infection is a leading cause of death.
Nine million new TB patients and 1.5 million TB deaths
occurred globally in 2013 [1]. TB remains a public threat
to human health in China. Combination chemotherapy
with anti-TB drugs (isoniazid, rifampicin, pyrazinamide
and ethambutol for 2 months and isoniazid and rifampi-
cin for 4 months) is the mainstay of TB treatment [2].
Most TB cases are cured using routine anti-TB therapy,
but some TB patients may develop severe side effects
[3–5] or drug-resistant TB [4, 6]. The adverse effects of
anti-TB drugs vary greatly among individuals [2, 7], and
these effects are closely related to disease progression
and the immune status of the patient [8]. Individualized
treatments that strengthen the body’s immune system
and enhance the efficacy and reduce the toxicity of anti-
TB drugs are a new method of treating TB [2, 8].
With more than 3000 years of clinical practice, Trad-
itional Chinese Medicine (TCM) is a fully institutionalized
medical system in China [9] and has been used to treat
TB for at least 500 years [10]. TCM enables individualized
health care [11, 12]. Diagnoses are based on the integrity
of the body and TCM syndrome differentiation, and dif-
ferent patients receive different prescriptions [11, 12]. The
TCM syndrome is the temporary state of the patient’s
comprehensive response and is the premise for treatment
[13]. Disease progression and the extent of damage are
generally assessed by inspection, auscultation, olfaction,
interrogation, and palpation in TCM [14, 15]. Patients
with the same disease can undergo different TCM syn-
dromes, thus providing an opportunity for personalized
medicine [14–16].
TB patients have been classified into three main TCM
syndromes: pulmonary Yin deficiency syndrome (PYD),
hyperactivity of fire due to Yin deficiency syndrome
(HFYD), and deficiency of Qi and Yin syndrome (DQY)
[17]. Modern medical studies have shown that the integra-
tion of Chinese and Western medicine based on the TCM
syndromes of TB patients can enhance the efficacy and
reduce the side effects of anti-TB drugs and improve the
immune response [18–20]. For example, Chinese herbs
with heat-clearing and detoxifying effects or nourishing
Yin and lowering fire effects, such as Astragalus membra-
naceus and Radix Paeoniae Rubra (Chishao), have been
used to treat TB [19–21]. Extracts from Astragalus mem-
branaceus greatly improve the phagocytosis of mycobac-
teria [19, 21]. Extracts from Radix Paeoniae Rubra elevate
the level of interleukin-8 [20] and drive the recruitment of
T lymphocytes and neutrophils at infection sites to in-
crease the bacteriostatic function of neutrophils [22, 23].
Extracts from Prunella vulgaris L. and Radix Sophorae
Flavescentis have been shown to strengthen cell-mediated
immunity in a rat model of multidrug-resistant TB [24].
However, TCM syndrome classification depends heav-
ily on the clinical experience of TCM practitioners, and
relevant fundamental experimental studies are lacking
[15, 25]. The current study used Arraystar Human
LncRNA Microarray technology to investigate the differ-
ential expression profiles of mRNAs and lncRNAs in
PYD, HFYD, and DQY patients with pulmonary TB. The
pathway enrichment of differentially expressed mRNAs
and clinical indexes were also analyzed using bioinfor-
matics methods.
Methods
Patients and control subjects
A total of 292 pretreated TB patients (aged 18 to 75 years),
including 92 PYD cases, 124 HFYD cases, and 76 DQY
cases, from Shaoxing Municipal Hospital (Shaoxing,
Zhejiang, China) were included in the current study. All
recruited TB patients were diagnosed according to the
diagnostic criteria of the Ministry of Health, China, and
met one of the following diagnostic criteria: positive spu-
tum culture or smear; typical active TB findings on chest
X-ray and CT scan; or pulmonary pathological lesions di-
agnosed as TB. TB cases with other diseases, such as
hepatitis B, diabetes, extra-pulmonary TB, AIDS, and im-
mune inhibitor users, were excluded. TB patients were
classified into PYD, HFYD, DQY syndromes according to
the ‘Standard of disease diagnosis and curative effect of
Traditional Chinese Medicine’ [18]. A total of 115 healthy
blood donors (aged 18 to 75 years) from Zhejiang Hospital
(Zhejiang, China) with no history of TB, hepatitis B, AIDS,
or other diseases were also included in the study.
Plasma samples were collected in heparin lithium-
anticoagulant tubes and centrifuged at 3000 rpm at 4 °C
for 10 min. Samples were dispensed into sterile cen-
trifuge tubes and stored at −80 °C. Data such as lipo-
protein-a, apolipoprotein-A1, apolipoprotein-B, total
cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), and triglycerides (TG)
levels were recorded for PYD, HFYD, and DQY cases
and healthy controls. Differences were analyzed by
one-way ANOVA followed by Tukey’s post-hoc test,
χ2 test, or unpaired t-test using GraphPad Prism 5
(GraphPad Software, Inc., USA) and one-sample t-test
after taking the logarithm using SPSS 16.0.
Chemicals and reagents
TRIzol® reagent was purchased from Invitrogen Life
Technologies, and the RNeasy Mini Kit was obtained
from Qiagen (Valencia, CA, USA). The Quick Amp
Labeling Kit (One-Color), gene expression hybridization
kit, gene expression wash buffer, and microarray scanner
were obtained from Agilent (California, USA). The mag-
netic stir plate was obtained from Corning Incorporated
(New York, USA).
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RNA isolation
Eleven PYD cases, 11 HFYD cases, 11 DQY cases, and
11 healthy controls were randomly chosen for the
following experiments. Each experimental group was
divided into three biological repeats. Plasma (200 μL)
from each specimen was used to extract total RNA with
TRIzol reagent (Invitrogen Life Technologies), and total
RNA was eluted in 85 μL of RNase-free water. An
RNeasy Mini Kit (Qiagen p/n 74104) was used to purify
total RNA according to the manufacturer’s instructions.
RNA quantity and concentration were evaluated using
a NanoDrop ND-1000 spectrophotometer at an absorb-
ance ratio of A260/A280. The nucleic acid was consid-
ered pure when the absorbance ratio was 1.8–2.0.
DNA microarray
The Human LncRNA Microarray V3.0 (Arraystar Co.
USA) allows the global profiling of human lncRNAs
and protein-coding transcripts. An estimated 30,586
lncRNAs were constructed using the most highly
respected public transcriptome databases, including
Refseq, Gencode, and UCSC known genes, and the
lncRNA microarray can detect 26,109 coding tran-
scripts. A specific exon or splice junction probe accur-
ately identified each transcript. Negative probes and
positive probes (housekeeping genes) were also printed
onto the array for hybridization quality control [26].
RNA labeling and array hybridization
Total RNA (1 μg) from each group was amplified and
transcribed into cyanine 3-labeled cRNA according to the
instructions for the Quick Amp Labeling Kit, One-Color
(Agilent). The labeled cRNAs were purified, and the
concentration and specific activity (pmol Cy3/μg cRNA)
were measured using a NanoDrop ND-1000 spectropho-
tometer. Hybridization was performed using an Agilent
Gene Expression Hybridization Kit according to the man-
ufacturer’s guidelines. Briefly, final 1× blocking agent and
1× fragmentation buffer were added to the labeled cRNA
and incubated at 60 °C to fragment RNA for 30 min. GE
Hybridization Buffer HI-RPM was mixed with the samples
to stop the fragmentation reaction. A gasket slide was
loaded into the Agilent SureHyb chamber before the
hybridization samples were dispensed into the gasket well,
and the Human LncRNA Array V3.0 slide was assem-
bled. The slides were hybridized in a hybridization oven
at 65 °C for 17 h, washed with Gene Expression Wash
Buffer, fixed and immediately scanned in an Agilent
Microarray Scanner (Agilent p/n G2565BA) [27].
Data analysis
The array images were analyzed using Agilent Feature
Extraction (version 11.0.1.1) software, and subsequent
quantile normalization and further data analyses were
performed in the GeneSpring GX v11.5.1 package (Agilent
Technologies). LncRNAs and mRNAs flagged as Present
or Marginal (“All Targets Value”) in at least three of 12
samples were chosen for further data analyses to remove
transcripts with unreliable expression. Significantly differ-
entially expressed lncRNAs and mRNAs between the two
groups were identified using Volcano Plot filtering, and
the expression patterns were analyzed using hierarchical
clustering [28].
lncRNA classification and pathway analysis
To explore potential functional relationship between
lncRNAs and related coding genes, significantly expressed
ncRNAs were classified into different subgroups, in-
cluding enhancer lncRNAs near coding genes, enhancer
lncRNA profiling, homeobox transcription factor (HOX)
cluster profiling, long intergenic noncoding RNAs
(lincRNAs) near coding genes, and lincRNA profiling.
Pathway analyses of differentially expressed mRNAs
were performed using the Kyoto Encyclopedia of Genes
and Genomes (KEGG) database. Gene ontology (GO)
was analyzed online (http://www.geneontology.org) to
determine the broad attributes of genes and gene prod-
ucts, which were classified into three domains: biological
process, cellular component, and molecular function. The
overlap between differentially expressed genes and GO an-
notation was also analyzed using Fisher’s exact test [28].
Results
Clinical characteristics of TB cases with different TCM
syndromes
PYD patients exhibited the following clinical symptoms
and signs: tussiculation; scant sticky and white sputum
or blood-stained sputum; dry mouth and pharynx; red
tongue with thin fur; and weak and rapid pulse (Fig. 1a).
HFYD patients exhibited the following clinical charac-
teristics: cough and breathlessness; hemoptysis; scant
sticky sputum with white or yellow color; dry mouth
and pharynx; red cheeks in the afternoon; tidal fever;
steaming sensation in the bone; night sweats; red or dark
red tongue with thin yellow or eroded fur; and weak and
rapid pulse (Fig. 1b).
DQY patients exhibited the following clinical symptoms:
cough with shortness of breath; clear and thin sputum;
hemoptysis; physical and mental fatigue; spontaneous
perspiration and night sweats; abdominal distension;
anorexia; loose stool; red, tender tongue with thin fur; and
weak and rapid pulse (Fig. 1c).
Statistical analysis of clinical indexes in TB cases
Statistical analyses of clinical indexes were performed
between 92 PYD cases (aged 40.13 ± 16.16 years), 124
HFYD cases (aged 40.85 ± 15.85 years), 76 DQY cases
(aged 43.95 ± 13.49 years), and 115 healthy controls
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(aged 39.30 ± 9.60 years). There were no significant dif-
ferences in gender or age between the four groups.
However, one-way ANOVA showed that the cholesterol
levels of TB patients were significantly different com-
pared to the healthy controls. The TC values in PYD
cases, HFYD cases, DQY cases, and healthy controls were
3.83 ± 1.06 mmol/L, 3.85 ± 0.80 mmol/L, 3.79 ± 0.87 mmol/
L, and 4.65 ± 0.52 mmol/L, respectively (P < 0.0001). HDL
values were 1.05 ± 0.36 mmol/L, 1.10 ± 0.40 mmol/L, 1.04
± 0.35 mmol/L, and 1.44 ± 0.26 mmol/L, respectively (P <
0.0001). LDL values were 2.74 ± 0.52 mmol/L, 2.31 ±
0.66 mmol/L, 2.30 ± 0.72 mmol/L, and 2.73 ± 0.52 mmol/L,
respectively (P = 0.0002). TG values were 1.08 ± 0.57 mmol/
L, 0.97 ± 0.41 mmol/L, 1.20 ± 0.89 mmol/L, and 0.95 ±
0.33 mmol/L, respectively (P = 0.0085). The TG value was
significantly higher in DQY cases than in PYD and DQY
cases (P = 0.0231, Table 1). One-sample t-tests were also
performed to analyze differences between TB patients with
different TCM syndromes and normal reference ranges
after taking the logarithm. Various significant differences
between TB patients with different TCM syndromes and
normal reference values of blood fat indexes were observed
(Additional file 1).
lncRNA microarray profiling of TB cases with different
TCM syndromes
The distribution of samples for microarray detection is
shown in Additional file 2. Microarray profiling of
30,586 lncRNAs was analyzed using Arraystar Human
LncRNA Microarray V3.0, and lncRNAs with fold
changes >2.00 and P < 0.05 were considered significantly
different. A total of 566 differentially expressed lncRNAs
were identified in PYD cases, including 347 up-regulated
and 219 down-regulated lncRNAs. Fifty-five differen-
tially expressed lncRNAs were identified in HFYD cases,
including 31 up-regulated and 24 down-regulated
lncRNAs. Sixty differentially expressed lncRNAs were
identified in DQY cases, including 35 up-regulated and
25 down-regulated lncRNAs. Most of the differentially
expressed lncRNAs were intergenic lncRNAs (61.34%),
Table 1 Characteristics of TB cases with PYD, HFYD and DQY syndromes
Healthy Controls (N = 115) PYD (N = 92) HFYD (N = 124) DQY (N = 76) P value
Age, age range (Mean ± SD) 39.30 ± 9.60 40.13 ± 16.16 40.85 ± 15.85 43.95 ± 13.49 0.1409a
Gender (female: male) 58/57 40/52 50/74 28/48 0.6558b
Abnormal chest radiograph (X, CT), no. (%) ND 92(100) 124(100) 76(100) /
Positive sputum smears, no. (%) ND 77(84.00) 100(81) 56(74.00) /
Lipoprotein a (mg/L) ND 261.41 ± 279.31 196.81 ± 189.58 264.72 ± 242.90 /
Apolipoprotein A1 (apoA1) (g/L) ND 1.05 ± 0.24 1.11 ± 0.28 1.07 ± 0.22 /
Apolipoprotein B (apoB) (g/L) ND 0.78 ± 0.24 0.81 ± 0.20 0.76 ± 0.17 /
Total cholesterol (TC) (mmol/L) 4.65 ± 0.52 3.83 ± 1.06 3.85 ± 0.80 3.79 ± 0.87 <0.0001*** a
High-density lipoprotein (HDL) (mmol/L) 1.44 ± 0.26 1.05 ± 0.36 1.10 ± 0.40 1.04 ± 0.35 <0.0001*** a
Low-density lipoprotein (LDL) (mmol/L) 2.74 ± 0.52 2.43 ± 1.20 2.31 ± 0.66 2.30 ± 0.72 0.0002*** a
Triglyceride (TG) (mmol/L) 0.95 ± 0.33 1.08 ± 0.57 0.97 ± 0.41 1.20 ± 0.89 0.0085** a
1.02 ± 0.49 1.20 ± 0.89 0.0252* c
There were no significant differences in gender and age between healthy controls and TB cases with PYD, HFYD and DQY syndromes. However, the cholesterol
levels of TB patients, such as TC, HDL, LDL, and TG, were significantly different from those of healthy controls
aP-value between healthy controls and TB cases with PYD, HFYD and DQY syndromes for one-way ANOVA followed by Tukey’s post-hoc test
bP-value between healthy controls and TB cases with PYD, HFYD and DQY syndromes for the χ2 test
cP-value between HFYD cases and other TB patients for the unpaired t-test
N number of subjects, ND not determined. *P < 0.05. **P < 0.01. *** P < 0.001
Fig. 1 Tongue manifestations of TB patients. a PYD syndrome of TB (red tongue with thin fur). b HFYD syndrome of TB (red or dark red tongue
with thin yellow or eroded fur). c DQY syndrome of TB (red and tender tongue with thin fur)
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natural antisense lncRNAs (14.63%), or intronic anti-
sense lncRNAs (11.49%). The remainder were exon
sense-overlapping lncRNAs, intron sense-overlapping
lncRNAs, and bidirectional lncRNAs. Figure 2 shows the
volcano plots and hierarchical clustering of the differen-
tially expressed lncRNAs.
mRNA microarray profiling of TB cases with different TCM
syndromes
Microarray profiling of 26,109 mRNAs was also per-
formed using Arraystar Human LncRNA Microarray
V3.0. A total of 634 differentially expressed mRNAs
were identified in PYD patients, including 404 up-
regulated and 230 down-regulated mRNAs. Forty-seven
differentially expressed mRNAs were identified in HFYD
patients, including 28 up-regulated and 19 down-
regulated mRNAs. Sixty-three differentially expressed
mRNAs were identified in DQY patients, including 44 up-
regulated and 19 down-regulated mRNAs. The volcano
plots and hierarchical clustering of differentially expressed
mRNAs are shown in Fig. 3.
Biological analysis
GO analysis was performed to determine the functions
of genes and gene products involved in biological pro-
cesses, cellular components and molecular functions.
Fisher’s exact test was performed to determine the over-
lap between the differentially expressed list and the GO
Fig. 2 lncRNA volcano plots and hierarchical clustering dendrogram of TB patients with distinctive TCM syndromes. a-c lncRNA volcano plots
(fold change >2.0 and P < 0.05). The vertical lines correspond to 2.0-fold up and down (log2 ratio), and the horizontal line represents a P-value of
0.05. Each point in the plot represents a different transcript. Transcripts are isolated based on statistical significance and magnitude of change.
Red squares represent significantly differentially expressed lncRNAs. d–f Hierarchical clustering dendrogram representing distinguishable lncRNA
expression profiling of samples. PYD: pulmonary Yin deficiency syndrome; HFYD: hyperactivity of fire due to Yin deficiency syndrome; DQY:
deficiency of Qi and Yin syndrome
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annotation. The significance of GO term enrichment
among the differentially expressed genes was shown using
P values. The highest enriched GO terms among differen-
tially expressed transcripts between TB syndromes were
cellular process (GO: 0009987; Ontology: biological
process, P = 4.23124E-05) (Fig. 4a), cytoplasm (GO:
0005737; Ontology: cellular component, P = 0.000754106)
(Fig. 4b), and protein binding (GO: 0005515; Ontology:
molecular function, P = 0.001293641) (Fig. 4c).
Pathway analysis indicated that 61 pathways were asso-
ciated with differentially expressed transcripts. The most
enriched pathway was “Hippo signaling pathway-Homo
sapiens (human)” (P = 0.000164), which was composed of
19 differentially expressed genes, and “Protein digestion
and absorption-Homo sapiens (human)” (P = 5.89017E-
05), which was also composed of 19 differentially
expressed genes (Fig. 4d). Seven transcripts (COL4A6,
PGA3, PGA4, PGA5, SLC1A5, SLC7A8, and SLC9A3) in-
volved in pathways of protein digestion and absorption
were up-regulated in PYD patients compared to HFYD
and DQY patients. Sixteen transcripts linked to oxidative
phosphorylation pathways were up-regulated in HFYD pa-
tients compared to the healthy controls, and two of these
transcripts (CYC1 and PPA2) were up-regulated in HFYD
patients compared to PYD and DQY patients. However,
two transcripts (ACOT1 and PTPLA) related to the fatty
acid elongation pathway were up-regulated in DQY pa-
tients compared to the healthy controls. We screened 20
Fig. 3 mRNA volcano plots and hierarchical clustering dendrogram of TB patients with distinctive TCM syndromes. a–c mRNA volcano plots (fold
change >2.0 and P < 0.05). The vertical lines correspond to 2.0-fold up and down (log2 ratio), and the horizontal line represents a P-value of 0.05.
Each point in the plot represents a different transcript. Transcripts are isolated based on statistical significance and magnitude of change. Red
squares represent significantly differentially expressed mRNAs. d–f Hierarchical clustering dendrogram representing distinguishable mRNA
expression profiling of the samples. PYD: pulmonary Yin deficiency syndrome; HFYD: hyperactivity of fire due to Yin deficiency syndrome; DQY:
deficiency of Qi and Yin syndrome
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Fig. 4 Gene ontology and pathway analyses of differentially expressed transcripts
Table 2 Differentially expressed lncRNAs and mRNAs in TB cases with PYD syndrome
Seqname GeneSymbol P-value Absolute Fold Change Associated
GeneA vs. control A vs. B A vs. C A vs. control A vs. B A vs. C
lncRNA
ENST00000536029 RP11-392P7.8 3.41E-07 8.50E-04 1.35E-04 47.87 44.37 44.85 GPRC5D
ENST00000543515 RP11-392P7.8 4.86E-05 1.72E-05 1.43E-04 39.01 44.01 31.53 GPRC5D
NR_036524 MICA 1.70E-05 1.20E-04 4.19E-05 44.00 36.07 29.72 MICA
ENST00000467458 RP11-796I2.2 1.48E-05 4.18E-07 1.91E-05 31.88 49.41 43.14 PRKAG2
uc002mej.1 AK056073 2.89E-06 1.40E-07 1.16E-07 5.28 5.46 5.52 ACSBG2
TCONS_00002486 XLOC_001036 5.51E-06 1.81E-06 7.44E-04 −5.57 −5.62 −4.58 KCNN3
DA401339 / 1.76E-04 8.76E-04 4.92E-04 −3.65 −4.94 −5.47 POU3F2
NR_036569 PILRB 1.73E-05 3.32E-05 1.42E-04 −4.32 −3.77 −4.53 PILRB
ENST00000458682 LINC00202 1.72E-03 1.94E-03 3.23E-03 −5.12 −5.48 −4.45 /
ENST00000517670 RP11-363E6.3 5.20E-05 9.24E-03 6.41E-04 −2.66 −2.75 −2.74 FABP5
mRNA
NM_033641 COL4A6 6.59E-04 1.23E-02 3.81E-05 3.04 3.63 2.76 /
NM_001079807 PGA3 1.32E-05 1.62E-03 9.73E-06 2.71 2.41 2.86 /
NM_001079808 PGA4 7.14E-06 2.51E-03 9.10E-05 5.07 5.30 4.12 /
NM_014224 PGA5 2.76E-06 2.84E-04 1.83E-02 2.88 4.08 2.81 /
ENST00000412532 SLC1A5 5.62E-03 2.18E-03 8.24E-04 4.78 11.40 8.89 /
NM_012244 SLC7A8 6.75E-05 2.77E-03 1.52E-03 4.45 4.81 3.47 /
NM_004174 SLC9A3 5.38E-06 5.64E-06 5.33E-06 4.85 4.81 4.86 /
NM_199235 COLEC11 3.00E-05 6.87E-04 5.33E-03 −6.77 −2.80 −4.07 /
NM_020664 DECR2 1.37E-05 7.59E-05 7.84E-04 −3.54 −3.61 −3.76 /
NM_018248 NEIL3 2.06E-04 8.97E-05 9.04E-05 −2.97 −2.97 −3.28 /
Twenty of the most significantly differentially expressed lncRNAs and mRNAs in TB cases with PYD syndrome compared to healthy controls and TB cases with
HFYD syndrome and DQY syndrome
Fold change >2: up-regulated; fold change < -2: down-regulated
A: PYD syndrome; B: HFYD syndrome; C: DQY syndrome
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differentially expressed mRNAs and lncRNAs in different
TCM syndromes of TB based on the fold changes and the
results of statistical analyses (Tables 2, 3 and 4).
Discussion
TCM states that disease occurs when Yin and Yang are
unbalanced or the flow of Qi and blood is disturbed [15].
The major causes of TB are infection by Mtb and Yin defi-
ciency [29]. Consumption of lung-Yin in the early stage of
TB causes pulmonary Yin deficiency syndrome (PYD).
Hyperactivity of liver-fire occurs with the development of
lung-Yin consumption and leads to hyperactivity of fire
due to Yin deficiency syndrome (HFYD). Harmony of Qi
and blood is disturbed in some chronic TB patients and
may cause a deficiency of Qi and Yin syndrome (DQY)
[29, 30]. There is a lack of research on the subtle changes
between different TCM syndromes, which is the major
challenge in the interpretation of the theories of TCM
using traditional methods [15, 17, 29]. We previously in-
vestigated the proteomic profiles of TB cases with TCM
syndromes using SELDI-TOF MS and iTRAQ-2DLC-MS/
MS and identified several differentially expressed serum
proteins in PYD, HFYD, and DQY cases [10, 31]. Thus,
subtle changes between different TCM syndromes of TB
were reflected in serum proteomics, suggesting that subtle
changes in PYD, HFYD and DQY cases may also be
reflected in transcriptomics.
In the current study, more differentially expressed
mRNAs and lncRNAs were detected in PYD patients
than HFYD and DQY patients. A total of 634 mRNAs
and 566 lncRNAs were differentially expressed in PYD
patients. However, 47 mRNAs and 55 lncRNAs were dif-
ferentially expressed in HFYD patients, and 63 mRNAs
and 60 lncRNAs were differentially expressed in DQY
patients. These results indicate that more abnormal gene
expression occurred in PYD patients.
A total of 19 mRNAs involved in the pathway of protein
digestion and absorption were differentially expressed in
PYD cases compared to the healthy controls, and seven
transcripts (COL4A6, PGA3, PGA4, PGA5, SLC1A5,
SLC7A8, and SLC9A3) were also up-regulated in PYD
cases compared to HFYD and DQY cases. COL4A6
Table 3 Differentially expressed lncRNAs and mRNAs in TB cases with HFYD syndrome
Seqname GeneSymbol P-value Absolute Fold Change Associated
GeneB vs. control B vs. A B vs. C B vs. control B vs. A B vs. C
lncRNA
TCONS_00008415 XLOC_003867 4.72E-02 1.71E-02 3.09E-02 7.24 14.65 10.20 /
NR_024499 FMR1-AS1 3.45E-02 2.96E-02 3.62E-02 6.64 8.06 7.25 FMR1
ENST00000510610 RP11-706C16.8 1.95E-04 1.72E-05 2.80E-05 4.57 6.58 6.39 LY6D
ENST00000521600 PVT1 8.03E-03 1.69E-03 1.88E-02 4.11 5.83 4.95 /
ENST00000448365 AC078842.4 6.88E-03 3.39E-03 2.75E-03 3.09 3.25 4.11 PTN
uc021pjm.1 HM358976 2.11E-04 5.85E-08 4.50E-05 −5.46 −4.76 −5.48 /
ENST00000441029 RP4-553 F4.2 4.27E-05 9.12E-04 4.26E-04 −3.49 −3.27 −4.65 ZNF341
ENST00000444112 AC005808.3 4.42E-03 2.13E-03 2.58E-02 −2.66 −3.30 −3.08 ZNF217
TCONS_00004246 XLOC_002087 7.60E-05 1.39E-03 3.01E-04 −4.72 −3.12 −3.88 /
ENST00000434072 GNG12-AS1 1.72E-03 1.54E-04 1.60E-03 −2.96 −6.46 −2.62 WLS
mRNA
NM_001916 CYC1 1.26E-04 1.33E-03 1.67E-04 5.39 5.61 7.44 /
NM_176869 PPA2 1.44E-02 1.67E-02 4.48E-02 2.70 2.02 2.06 /
ENST00000418434 CASP5 2.61E-02 3.75E-02 1.67E-02 4.29 3.82 5.21 /
NM_182609 ZNF677 8.52E-03 2.47E-02 2.56E-03 4.35 3.61 5.60 /
NM_001135086 PRSS41 3.90E-02 1.15E-02 4.07E-02 4.34 9.42 4.54 /
NM_207174 ABCG1 4.65E-03 2.59E-03 3.68E-02 6.35 8.32 4.40 /
NM_001101 ACTB 1.95E-03 3.10E-04 1.99E-03 −2.45 −4.22 −3.09 /
NM_001135575 C6orf228 1.23E-03 1.10E-03 3.89E-03 −6.66 −7.04 −5.13 /
NM_001166415 EHHADH 3.06E-02 2.25E-02 1.93E-02 −2.79 −2.87 −3.15 /
NM_152496 MANEAL 2.40E-02 1.28E-02 1.36E-02 −5.78 −8.54 −8.88 /
Twenty of the most significantly differentially expressed lncRNAs and mRNA in TB cases with HFYD syndrome compared to healthy controls and TB cases with
PYD syndrome and DQY syndrome
Fold change >2: up-regulated; fold change < -2: down-regulated
A: PYD syndrome; B: HFYD syndrome; C: DQY syndrome
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encodes the alpha-6 chain of type IV collagen of basal
membranes and is related to the prognosis of esophageal
squamous cell carcinoma [32]. PGA3, PGA4, and PGA5
encode pepsinogen A (PGA), and the differential expres-
sion of PGA3, PGA4, and PGA5 is related to the pre-
neoplastic nature in patients with Barrett’s esophagus [33].
SLC7A8 and SLC9A3 are solute carrier family genes, and
the product of SLC7A8 participates in the transport of
amino acids [34]. SLC9A3 encodes Na(+)/H(+) exchanger
(NHE3), which is down-regulated in patients with ulcera-
tive colitis [35]. TCM considers the spleen the ‘mother
organ’ to the lungs, and thus the spleen may be similarly
affected by conditions that affect the ‘child organ’ [36].
PYD syndrome often leads to spleen deficiency, and the
clinical symptoms of PYD patients with spleen deficiency
were anorexia, poor appetite, and loose stools [36]. Pa-
tients with spleen deficiency are generally characterized by
digestive system disorders [37]. Therefore, we suspect that
differentially expressed mRNAs (COL4A6, PGA3, PGA4,
PGA5, SLC1A5, SLC7A8, and SLC9A3) involved in the
protein digestion and absorption pathway may be related
to the spleen deficiency in PYD patients.
The expression of 16 mRNAs involved in the pathway
of oxidative phosphorylation was significantly increased in
HFYD patients compared to the healthy controls, and two
mRNAs (CYC1, PPA2) were also up-regulated. CYC1 en-
codes the cytochrome c1 subunit of respiratory chain
complex III, which mediates the transfer of electrons from
cytochrome b to cytochrome c during oxidative phosphor-
ylation [38–40]. The PPA2 gene encodes mitochondrial
pyrophosphatase 2, which catalyzes the hydrolysis of
pyrophosphate to generate inorganic phosphate in cellular
enzymatic reactions [41]. PPA2 is required for the main-
tenance of mitochondrial DNA and the synthesis of DNA,
RNA, cAMP, and cGMP [41]. Oxidative phosphorylation
is the major source of ATP and energy production, and
mitochondria are the primary site of oxidative phos-
phorylation reactions [42]. Pulmonary TB is a typical
consumptive disease with symptoms of weight loss,
energy expenditure, and fat reduction [43]. Therefore,
Table 4 Differentially expressed lncRNAs and mRNAs in TB cases with DQY syndrome
Seqname Gene Symbol s-value Absolute Fold Change Associated
GeneC vs. control C vs. A C vs. B C vs. control C vs. A C vs. B
lncRNA
ENST00000412526 LINC00161 1.07E-03 1.72E-06 7.63E-04 4.59 6.66 4.13 /
uc004erg.1 BC028211 2.34E-02 4.18E-02 1.53E-02 5.21 4.40 7.54 SLC25A5
NR_036516 C17orf62 1.13E-05 1.19E-05 2.03E-04 9.79 9.70 7.45 C17orf62
ENST00000434601 LINC00422 1.05E-02 1.62E-02 2.06E-02 10.46 7.46 6.49 /
ENST00000522460 RP1-84O15.2 8.86E-03 9.02E-03 9.01E-03 7.49 7.42 7.42 /
ENST00000452110 PI4KAP1 1.63E-02 8.34E-05 8.64E-03 −2.42 −8.92 5.27 /
BM728564 / 1.88E-03 5.54E-03 4.47E-02 −9.20 −5.69 3.54 /
ENST00000528696 CTD-3076O17.1 1.88E-03 4.12E-02 1.57E-02 −2.15 −4.07 −2.09 ADAMTS17
ENST00000582033 CTD-2124B20.2 9.98E-03 1.21E-04 1.86E-04 −2.81 −4.08 −2.39 /
TCONS_00012029 XLOC_005561 9.25E-05 3.03E-02 1.68E-04 −2.90 −3.51 −2.29 /
mRNA
NM_013322 SNX10 2.73E-02 2.72E-02 2.99E-02 7.36 7.39 6.99 /
NM_004436 ENSA 9.27E-04 9.47E-04 4.01E-03 8.45 8.36 6.76 /
NM_153182 MINA 5.81E-03 5.91E-03 5.90E-03 10.37 10.27 10.28 /
NM_014178 STXBP6 1.50E-07 1.83E-07 1.59E-07 15.71 15.56 15.56 /
NM_183375 PRSS48 3.58E-05 1.94E-06 1.27E-06 11.26 11.92 12.46 /
NM_001037161 ACOT1 2.39E-02 7.52E-02 3.50E-01 2.15 1.68 1.67 /
NM_014241 PTPLA 2.25E-02 7.65E-01 5.54E-02 3.11 1.05 2.17 /
NM_001040443 PHF11 1.82E-02 1.01E-02 2.71E-02 −2.71 −3.85 −2.93 /
NM_001099455 CPPED1 1.21E-03 2.01E-03 2.32E-02 −5.78 −4.58 −2.25 /
NM_080627 SOGA1 7.61E-04 2.65E-04 4.96E-04 −2.48 −4.33 −3.32 /
Twenty of the most significantly differentially expressed lncRNAs and mRNA in TB cases with DQY syndrome compared to healthy control s and TB cases with
PYD syndrome and HFYD syndrome
Fold change >2: up-regulated; fold change < -2: down-regulated
A: PYD syndrome; B: HFYD syndrome; C: DQY syndrome
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increased expression of CYC1 and PPA2 mRNAs in the
pathway of oxidative phosphorylation may be linked to
the energy consumption observed in HFYD syndrome.
Two mRNAs (ACOT1, PTPLA) involved in the fatty
acid elongation pathway were up-regulated in DQY pa-
tients compared to the healthy controls. ACOT1 encodes
acyl-CoA thioesterase 1, which hydrolyzes acyl-CoAs into
free fatty acids and CoASH, thereby regulating intracellu-
lar levels of free fatty acids and CoASH [44]. PTPLA (also
known as HACD1) encodes 3-hydroxyacyl-CoA dehydra-
tase 1, which affects the third step (dehydration) in the
elongation of very long chain fatty acids and is neces-
sary for muscle function [45]. Clinical analyses revealed
that cholesterol levels (TG, TC, HDL, LDL) differed sig-
nificantly between TB patients and healthy controls,
and the value of TG was significantly increased in DQY
patients compared to PYD and DQY patients (Table 1).
The hydrolysis of triglyceride (fat) from TB patients is
necessary for the survival and virulence of Mycobacter-
ium tuberculosis [46, 47]. Therefore, the up-regulated
ACOT1 and PTPLA mRNAs linked to the fatty acid
elongation pathway may be associated with the abnor-
mality of blood fats in DQY syndrome.
Differentially expressed lncRNAs were identified in
PYD, HFYD, and DQY patients. Ten differentially
expressed lncRNAs for each TCM syndrome of TB were
screened based on fold changes. G-protein coupled re-
ceptor family C group 5 member D, MHC class I
polypeptide-related sequence A isoform 2,5’-AMP-acti-
vated protein kinase subunit gamma-2 isoform a, and
paired immunoglobulin-like type 2 receptor beta pre-
cursor were the associated proteins of differentially
expressed lncRNAs in PYD cases. Lymphocyte antigen
6D precursor, pleiotrophin precursor, and zinc finger
protein were the associated proteins of differentially
expressed lncRNAs in HFYD patients. ADP/ATP trans-
locase 2 and a disintegrin and metalloproteinase with
thrombospondin motifs 17 preproprotein were the as-
sociated proteins of differentially expressed lncRNAs in
DQY patients. However, the functions of most lncRNAs
have not been reported. Therefore, the differentially
expressed lncRNAs in PYD, HFYD, and DQY patients
and their functional relationship with the subtle changes
between different TCM syndromes of TB requires further
investigation.
Conclusion
This study revealed significantly altered lncRNA and
mRNA expression profiles in the PYD, HFYD and DQY
syndromes of TB. The pathway enrichment of differen-
tially expressed transcripts was also analyzed using bio-
informatics methods. The enhanced expression of
mRNAs involved in the protein digestion and absorption
pathway in PYD patients may be related to the spleen
deficiency in PYD syndrome. The increased expression
of CYC1 and PPA2 mRNAs in the oxidative phosphoryl-
ation pathway may be linked to the energy consumption
in HFYD syndrome. The up-regulated ACOT1 and
PTPLA mRNAs linked to the fatty acid elongation path-
way may be associated with the abnormality of blood
fats in DQY syndrome. These results indicated that the
expression profile analysis of lncRNAs and mRNAs may
be a novel method to explore the biological essence of
TCM syndromes. However, the functional roles of
lncRNAs and mRNAs in different TCM syndromes of
TB require further investigation.
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